Acorda Therapeutics Completes Enrollment of Phase 3 Clinical Trial of Fampridine-SR

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that it has completed enrollment for its Phase 3 clinical trial of Fampridine-SR in multiple sclerosis (MS). The trial is designed to evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS. 240 patients were enrolled at 39 clinical trial sites in the United States and Canada. The Company expects data from the trial in the second quarter of 2008.